Influenza: Seeking help: B cells adapting to flu variability

Science Translational Medicine

Volumn 6, Issue 246, 2014, Pages

  Van Der Most, Robbert G ^a   Roman, François P ^a   Innis, Bruce ^b   Hanon, Emmanuel ^a   Vaughn, David W ^a   Gillard, Paul ^a   Walravens, Karl ^a   Wettendorf, Martine ^a  

^a GSK   (Belgium)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIBODY; HEMAGGLUTININ; INFLUENZA VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VIRUS HEMAGGLUTININ;

ADAPTATION; ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ANTIGENICITY; B LYMPHOCYTE; B LYMPHOCYTE ADAPTABILITY; CD4+ T LYMPHOCYTE; DRUG COMPETITION; GENE MUTATION; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA REPLICATION; SOMATIC HYPERMUTATION; SOMATIC MUTATION; VACCINATION; VIRUS STRAIN; HELPER CELL; IMMUNOLOGY; INFLUENZA;

ADAPTATION, PHYSIOLOGICAL; ADJUVANTS, IMMUNOLOGIC; B-LYMPHOCYTES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84927171394     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008409     Document Type: Review

References (56)

1. J. Wrammert, K. Smith, J. Miller, W. A. Langley, K. Kokko, C. Larsen, N.-Y. Zheng, I. Mays, L. Garman, C. Helms, J. James, G. M. Air, J. D. Capra, R. Ahmed, P. C. Wilson, Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667-671 (2008). (Pubitemid 351769295)
2. I. Leroux-Roels, A. Borkowski, T. Vanwolleghem, M. Dramé, F. Clement, E. Hons, J.-M. Devaster, G. Leroux-Roels, Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 370, 580-589 (2007). (Pubitemid 47247854)
3. I. Leroux-Roels, F. Roman, S. Forgus, C. Maes, F. De Boever, M. Dramé, P. Gillard, R. van der Most, M. Van Mechelen, E. Hanon, G. Leroux-Roels, Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open nonrandomised extension of a double-blind randomised primary study. Vaccine 28, 849-857 (2010).
4. J. H. Kim, W. G. Davis, S. Sambhara, J. Jacob, Strategies to alleviate original antigenic sin responses to influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 109, 13751-13756 (2012).
5. G. Galli, K. Hancock, K. Hoschler, J. DeVos, M. Praus, M. Bardelli, C. Malzone, F. Castellino, C. Gentile, T. McNally, G. Del Giudice, A. Banzhoff, V. Brauer, E. Montomoli, M. Zambon, J. Katz, K. Nicholson, I. Stephenson, Fast rise of broadly cross-reactive antibodies after boosting longlived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl. Acad. Sci. U. S. A. 106, 7962-7967 (2009).
6. S. Alam, Z. A. Knowlden, M. Y. Sangster, A. J. Sant, CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection. J. Virol. 88, 314-324 (2014).
7. S. Khurana, W. Chearwae, F. Castellino, J. Manischewitz, L. R. King, A. Honorkiewicz, M. T. Rock, K. M. Edwards, G. Del Giudice, R. Rappuoli, H. Golding, Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2, 15ra5 (2010).
8. S. Khurana, N. Verma, J. W. Yewdell, A. K. Hilbert, F. Castellino, M. Lattanzi, G. Del Giudice, R. Rappuoli, H. Golding, MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3, 85ra48 (2011).
9. P. Moris, R. van der Most, I. Leroux-Roels, F. Clement, M. Dramé, E. Hanon, G. G. Leroux-Roels, M. Van Mechelen, H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J. Clin. Immunol. 31, 443-454 (2011).
10. F. Roman, F. Clément, W. Dewé, K. Walravens, C. Maes, J. Willekens, F. De Boever, E. Hanon, G. Leroux-Roels, Eff ect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin. Vaccine Immunol. 18, 835-843 (2011).
11. G. Galli, D. Medini, E. Borgogni, L. Zedda, M. Bardelli, C. Malzone, S. Nuti, S. Tavarini, C. Sammicheli, A. K. Hilbert, V. Brauer, A. Banzhoff, R. Rappuoli, G. Del Giudice, F. Castellino, Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. U. S. A. 106, 3877-3882 (2009).
12. E. Faenzi, L. Zedda, M. Bardelli, F. Spensieri, E. Borgogni, G. Volpini, F. Buricchi, F. L. Pasini, P. L. Capecchi, F. Montanaro, R. Belli, M. Lattanzi, S. Piccirella, E. Montomoli, S. S. Ahmed, R. Rappuoli, G. Del Giudice, O. Finco, F. Castellino, G. Galli, One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. Vaccine 30, 4086-4094 (2012).
13. S. Morel, A. Didierlaurent, P. Bourguignon, S. Delhaye, B. Baras, V. Jacob, C. Planty, A. Elouahabi, P. Harvengt, H. Carlsen, A. Kielland, P. Chomez, N. Garçon, M. Van Mechelen, Adjuvant System AS03 containing a-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29, 2461-2473 (2011).
14. D. T. O'Hagan, G. S. Ott, E. De Gregorio, A. Seubert, The mechanism of action of MF59-An innately attractive adjuvant formulation. Vaccine 30, 4341-4348 (2012).
15. C. L. Goins, C. P. Chappell, R. Shashidharamurthy, P. Selvaraj, J. Jacob, Immune complex-mediated enhancement of secondary antibody responses. J. Immunol. 184, 6293-6298 (2010).
16. S. Khurana, D. Frasca, B. Blomberg, H. Golding, AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans. PLOS Pathog. 8, e1002920 (2012).
17. J. Wrammert, D. Koutsonanos, G.-M. Li, S. Edupuganti, J. Sui, M. Morrissey, M. McCausland, I. Skountzou, M. Hornig, W. I. Lipkin, A. Mehta, B. Razavi, C. Del Rio, N.-Y. Zheng, J.-H. Lee, M. Huang, Z. Ali, K. Kaur, S. Andrews, R. R. Amara, Y. Wang, S. R. Das, C. D. O'Donnell, J. W. Yewdell, K. Subbarao, W. A. Marasco, M. J. Mulligan, R. Compans, R. Ahmed, P. C. Wilson, Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193 (2011).
18. M. S. Miller, T. J. Gardner, F. Krammer, L. C. Aguado, D. Tortorella, C. F. Basler, P. Palese, Neutralizing antibodies against previously encountered influenza virus strains increase over time: A longitudinal analysis. Sci. Transl. Med. 5, 198ra107 (2013).
19. S. Crotty, Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621-663 (2011).
20. R. Morita, N. Schmitt, S. E. Bentebibel, R. Ranganathan, L. Bourdery, G. Zurawski, E. Foucat, M. Dullaers, S. Oh, N. Sabzghabaei, E. M. Lavecchio, M. Punaro, V. Pascual, J. Banchereau, H. Ueno, Human blood CXCR5 +CD4+ T cells are counterparts of T follicular cells and contain specific subsets that diff erentially support antibody secretion. Immunity 34, 108-121 (2011).
21. S. E. Bentebibel, S. Lopez, G. Obermoser, N. Schmitt, C. Mueller, C. Harrod, E. Flano, A. Mejias, R. A. Albrecht, D. Blankenship, H. Xu, V. Pascual, J. Banchereau, A. Garcia-Sastre, A. K. Palucka, O. Ramilo, H. Ueno, Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci. Transl. Med. 5, 176ra32 (2013).
22. F. Spensieri, E. Borgogni, L. Zedda, M. Bardelli, F. Buricchi, G. Volpini, E. Fragapane, S. Tavarini, O. Finco, R. Rappuoli, G. Del Giudice, G. Galli, F. Castellino, Human circulating influenza-CD4+ ICOS1 +IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. Proc. Natl. Acad. Sci. U. S. A. 110, 14330-14335 (2013).
23. N. Fazilleau, L. J. McHeyzer-Williams, H. Rosen, M. G. McHeyzer-Williams, The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat. Immunol. 10, 375-384 (2009).
24. E. Fragapane, R. Gasparini, F. Schioppa, F. Laghi-Pasini, E. Montomoli, A. Banzhoff, A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin. Vaccine Immunol. 17, 1817-1819 (2010).
25. I. Leroux-Roels, R. Bernhard, P. Gérard, M. Dramé, E. Hanon, G. Leroux-Roels, Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLOS One 3, e1665 (2008).
26. K. Hancock, V. Veguilla, X. Lu, W. Zhong, E. N. Butler, H. Sun, F. Liu, L. Dong, J. R. DeVos, P. M. Gargiullo, T. L. Brammer, N. J. Cox, T. M. Tumpey, J. M. Katz, Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361, 1945-1952 (2009).
27. J. L. Nayak, S. Alam, A. J. Sant, Cutting edge: Heterosubtypic influenza infection antagonizes elicitation of immunological reactivity to hemagglutinin. J. Immunol. 191, 1001-1005 (2013).
28. S. Crotty, P. Felgner, H. Davies, J. Glidewell, L. Villarreal, R. Ahmed, Cutting edge: Long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171, 4969-4973 (2003). (Pubitemid 37432774)
29. K. L. Good-Jacobson, M. J. Shlomchik, Plasticity and heterogeneity in the generation of memory B cells and long-lived plasma cells: The influence of germinal center interactions and dynamics. J. Immunol. 185, 3117-3125 (2010).
30. N. Verma, M. Dimitrova, D. M. Carter, C. J. Crevar, T. M. Ross, H. Golding, S. Khurana, Influenza virus H1N1pdm09 infections in the young and old: Evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 domain) in the elderly than in young adults and children. J. Virol. 86, 5515-5522 (2012).
31. N. Andrews, P. Waight, C.-F. Yung, E. Miller, Age-specific eff ectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J. Infect. Dis. 203, 32-39 (2011).
32. L. Coudeville, F. Bailleux, B. Riche, F. Megas, P. Andre, R. Ecochard, Relationship between haemagglutinationinhibiting antibody titres and clinical protection against influenza: Development and application of a bayesian random-eff ects model. BMC Med. Res. Methodol. 10, 18 (2010).
33. B. J. Cowling, S. Ng, E. S. Ma, C. K. Cheng, W. Wai, V. J. Fang, K. H. Chan, D. K. Ip, S. S. Chiu, J. S. Peiris, G. M. Leung, Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin. Infect. Dis. 51, 1370-1379 (2010).
34. N. Z. Janjua, D. M. Skowronski, T. S. Hottes, W. Osei, E. Adams, M. Petric, S. Sabaiduc, T. Chan, A. Mak, M. Lem, P. Tang, D. M. Patrick, G. De Serres, D. Bowering, Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: First detection of the association in British Columbia, Canada. Clin. Infect. Dis. 51, 1017-1027 (2010).
35. D. M. Skowronski, G. De Serres, N. S. Crowcroft, N. Z. Janjua, N. Boulianne, T. S. Hottes, L. C. Rosella, J. A. Dickinson, R. Gilca, P. Sethi, N. Ouhoummane, D. J. Willison, I. Rouleau, M. Petric, K. Fonseca, S. J. Drews, A. Rebbapragada, H. Charest, M.-E. Hamelin, G. Boivin, J. L. Gardy, Y. Li, T. L. Kwindt, D. M. Patrick, R. C. Brunham, Canadian SAVOIR Team, Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during springsummer 2009: Four observational studies from Canada. PLOS Med. 7, e1000258 (2010).
36. S. Mahmud, G. Hammond, L. Elliott, T. Hilderman, C. Kurbis, P. Caetano, P. Van Caeseele, J. Kettner, M. Dawood, Eff ectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: Population-based case-control study. Vaccine 29, 7975-7981 (2011).
37. C. Viboud, L. Simonsen, Does seasonal influenza vaccination increase the risk of illness with the 2009 A/H1N1 pandemic virus? PLOS Med. 7, e1000259 (2010).
38. H. Kelly, S. Barry, K. Laurie, G. Mercer, Seasonal influenza vaccination and the risk of infection with pandemic influenza: A possible illustration of non-specific temporary immunity following infection. Euro Surveill. 15, 19722 (2010).
39. T. W. Hoskins, J. R. Davies, A. J. Smith, C. L. Miller, A. Allchin, Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 313, 33-35 (1979). (Pubitemid 9084475)
40. W. A. Keitel, T. R. Cate, R. B. Couch, Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am. J. Epidemiol. 127, 353-364 (1988). (Pubitemid 18056387)
41. G. Risi, L. Frenette, J. M. Langley, P. Li, D. Riff, E. Sheldon, D. W. Vaughn, L. Fries, Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two diff erent formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months. Vaccine 29, 6408-6418 (2011).
42. I. Stephenson, K. G. Nicholson, K. Hoschler, M. C. Zambon, K. Hancock, J. DeVos, J. M. Katz, M. Praus, A. Banzhoff, Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N. Engl. J. Med. 359, 1631-1633 (2008).
43. T. Nolan, P. C. Richmond, N. T. Formica, K. Höschler, M. V. Skeljo, T. Stoney, J. McVernon, G. Hartel, D. C. Sawlwin, J. Bennet, D. Ryan, R. L. Basser, M. C. Zambon, Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26, 6383-6391 (2008).
44. N. J. Andrews, W. T. Walker, A. Finn, P. T. Heath, A. C. Collinson, A. J. Pollard, M. D. Snape, S. N. Faust, P. A. Waight, K. Hoschler, L. Sheasby, C. Waddington, S. Kerridge, J. Chalk, A. Reiner, T. John, M. Fletcher, R. Allen, N. Fineman, S. Wilkins, M. Casey, L. Michaelis, C. Oeser, I. Okike, S. Ladhani, E. Miller, Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine 29, 7913-7919 (2011).
45. P. Van Damme, F. Kafeja, V. Bambure, E. Hanon, P. Moris, F. Roman, P. Gillard, Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: An open-label, randomized study in adults aged 18-60 years and older. Hum. Vaccin. Immunother. 9, 1512-1522 (2013).
46. F. Roman, T. Vaman, F. Kafeja, E. Hanon, P. Van Damme, AS03 (A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin. Infect. Dis. 51, 668-677 (2010).
47. S. Roy-Ghanta, R. van der Most, P. Li, D. W. Vaughn, Responses to A (H1N1) pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: A randomized, observer-blind, controlled study. J. Infect. Dis. 10.1093/infdis/jiu284 (26 May 2014).
48. E. Huijskens, J. Rossen, P. Mulder, R. van Beek, H. van Vugt, J. Verbakel, G. Rimmelzwaan, M. Koopmans, M. Peeters, Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. Clin. Vaccine Immunol. 18, 1401-1405 (2011).
49. T. Nolan, J. McVernon, M. Skeljo, P. Richmond, U. Wadia, S. Lambert, M. Nissen, H. Marshall, R. Booy, L. Heron, G. Hartel, M. Lai, R. Basser, C. Gittleson, M. Greenberg, Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children: A randomized trial. J. Am. Med. Assoc. 303, 37-46 (2010).
50. Y. S. Choi, Y. H. Baek, W. Kang, S. J. Nam, J. Lee, S. You, D. Y. Chang, J. C. Youn, Y. K. Choi, E. C. Shin, Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination. Clin. Vaccine Immunol. 18, 1519-1523 (2011).
51. J. Wu, X. Zhong, C. K. Li, J. F. Zhou, M. Lu, K. Y. Huang, M. Dong, Y. Liu, F. J. Luo, N. Du, C. Chui, L. Q. Liu, N. M. Smith, B. Li, N. M. Shi, L. F. Song, Y. Gao, D. Y. Wang, X. Wang, W. F. Zhu, Y. Yan, Z. Li, J. T. Chen, A. J. McMichael, W. D. Yin, X. N. Xu, Y. Shu, Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans. Vaccine 29, 1009-1016 (2011).
52. W. T. Walker, P. de Whalley, N. Andrews, C. Oeser, M. Casey, L. Michaelis, K. Hoschler, C. Harrill, P. Moulsdale, B. Thompson, C. Jones, J. Chalk, S. Kerridge, T. M. John, I. Okike, S. Ladhani, R. Tomlinson, P. T. Heath, E. Miller, S. N. Faust, M. D. Snape, A. Finn, A. J. Pollard, H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: A multicenter follow-on study. Clin. Infect. Dis. 54, 661-669 (2012).
53. J. M. Langley, L. Frenette, L. Chu, S. McNeil, S. Halperin, P. Li, D. Vaughn, A randomized, controlled non-inferiority trial comparing A (H1N1) pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. BMC Infect. Dis. 12, 279 (2012).
54. M. Peeters, S. Regner, T. Vaman, J. M. Devaster, L. Rombo, Safety and immunogenicity of an AS03-adjuvanted A (H1N1) pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: Data from two multicentre randomised trials. Vaccine 30, 6483-6491 (2012).
55. Z. Vajo, F. Tamas, L. Sinka, I. Jankovics, Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: A multicentre, randomised controlled trial. Lancet 375, 49-55 (2010).
56. S. Nabeshima, K. Kashiwagi, M. Murata, Y. Kanamoto, N. Furusyo, J. Hayashi, Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J. Med. Virol. 79, 320-325 (2007). (Pubitemid 46213197)